Table V.
Comparisons of the results from the transcriptomic and proteomic studies.
| Protein identified in the proteomic study (33) | Corresponding gene | Microarray probe | Protein accumulation | Gene expression | Concordant |
|---|---|---|---|---|---|
| Actin γ1 | ACTG1 | Target-specific | In HV present only in BM, in AML higher in CR-short | In HV higher in PB, in AML higher in CR-short | Partially |
| α-actinin | ACTN4 | For ACTN1 | Higher in AML | Slightly lower in AML | No |
| Fructose-bisphosphate aldolase A | ALDOA | For ALDOC | In HV present only in BM | In HV higher in PB | No |
| Annexin I | ANXA1 | Target-specific | In HV higher in BM, higher in AML vs. HV and in CR vs. RES AML | In HV higher in BM, no difference between AML and HV, lower in CR vs. RES AML | No |
| Annexin III | ANXA3 | Target-specific | In HV higher in PB, in AML present only in M2 | In HV higher in BM, higher in AML vs. HV, higher in AML M1 vs. M2 | No |
| Rho GDP-dissociation inhibitor 2 | ARHGDIB | For ARHGAP4, ARHGEF1, ARHGEF12 | In HV higher in BM, higher in AML vs. HV | In HV higher in PB, ARHGEF12 and ARHGAP4 - higher in AML, ARHGEF1 - slightly lower in AML | Partially |
| Catalase | CAT | Target-specific | In HV higher in PB, higher in AML and in AML M2 vs. M1 | In HV higher in PB, slightly higher in AML vs. HV, higher in AML M2 vs. M1 | Yes |
| Cofilin-1 | CFL1 | Target-specific | In HV higher in PB | In HV slightly higher in PB | Yes |
| α-enolase (ENO1 protein) | ENO1 | Target-specific | In HV higher in BM | In HV higher in PB, significantly higher in AML vs. HV | No |
| Glutathione transferase ω | GSTO (1,2) | For GSTP1 | Present only in AML CR | Significantly higher in AML, slightly lower in CR | No |
| Tumor rejection antigen (Gp96) | HSP90B1 | Target-specific | In HV higher in PB, lower in AML vs. HV | In HV higher in PB, higher in AML vs. HV | Partially |
| L-Plastin (lymphocyte cytosolic protein 1) | LCP1 | Target-specific | Present only in AML M2 | Significantly lower in AML vs. HV, higher in AML M1 | No |
| Pyruvate kinase | PKM | Target-specific | Much higher in AML vs. HV | Significantly higher in AML vs. HV | Yes |
| Purine nucleoside phosphorylase | PNP | Target-specific | In HV higher in BM, lower in AML | In HV higher in PB, higher in AML | No |
| Acetyl-cypa:cyclosporine complex [peptidylprolyl isomerase A (cyclophilin A)] | PPIA | For PPIF | In HV higher in PB | In HV no difference between PB and BM, higher in AML vs. HV | No |
| Peroxiredoxin-2 | PRDX2 | Target-specific | In HV higher in BM, higher in AML vs. HV PB, lower in AML vs. HV BM | In HV higher in BM, slightly lower in AML vs. HV | Partially |
| Histone-binding protein RBBP4 (retinoblastoma binding protein) | RBBP4 | Target-specific | Higher in AML, in HV merely detectable | Slightly lower in AML vs. HV | No |
| Tropomyosin α | TPM1 | Target-specific | In HV present only in PB, much lower in AML vs. HV | In HV higher in BM, lower in AML vs. HV | Partially |
| Tubulin β | TUBB | Target-specific | In HV higher in BM, lower in AML vs. HV | In HV higher in BM, higher in AML vs. HV | Partially |
| 14-3-3 protein ζ/δ | YWHAZ | For YWHAQ | In HV higher in PB, lower in AML vs. HV | In HV higher in PB, slightly lower in AML vs. HV | Yes |